Núcleos de concepto en el estudio de la fosa pterigomaxilar : Enfoque pedagógico

La fosa pterigomaxilar constituye una de las cavidades comunes a la cara y el cráneo. Tiene forma de una pirámide cuadrangular, de base superior y vértice inferior. Se encuentra ubicada entre la apófisis pterigoides del hueso esfenoides por detrás, la cara posterior de la tuberosidad del maxilar superior hacia adelante, y la porción horizontal del ala mayor del esfenoides y parte de la escama del hueso temporal hacia arriba. Su trasfondo, solo descrito por algunos autores, está limitado hacia adentro por el hueso palatino, en cuyo borde superior presenta el orificio (esfenopalatino) que comunica con las fosas nasales. La complejidad de sus paredes y las diversas comunicaciones con espacios vecinos hace que los alumnos presenten dificultades en su estudio, y plantean al docente el desafío de generar nuevas herramientas pedagógicas.Facultad de Ciencias Médica

Evaluation of the effectiveness of some drugs for the treatment of canine hepatozoonosis

La hepatozoonosis canina es una enfermedad parasitaria, adquirida por la ingestión de garrapatas infectadas con protozoarios del género Hepatozoon (H). Hepatozoon canis y Hepatozoon americanum son las dos especies que pueden infectar al perro. La presentación clínica de la infección con Hepatozoon canis es muy variable, pudiendo ser asintomática o manifestarse con signos de enfermedad leves a severos. Los exámenes hematológicos revelan ligera anemia no regenerativa, marcada leucocitosis neutrofílica con desvío a la izquierda y monocitosis en los casos de hepatozoonosis clínica. El diagnóstico se realiza mediante la visualización mediante el microscopio óptico de los gamontes en neutrófilos y monocitos en frotis de sangre coloreados. No existe, hasta el momento, un tratamiento eficaz para esta parasitosis. El fármaco más utilizado es el dipropionato de imidocarb, aunque con resultados variables. El objetivo de este trabajo fue evaluar tres opciones terapéuticas para la erradicación de Hepatozoon spp. de la sangre de perros infectados. Se utilizaron 18 perros parasitados naturalmente y se evaluaron tres fármacos: dipropionato de imidocarb, toltrazuril y espiramicina. En todos los perros tratados disminuyó el promedio de infección, presentando similares valores medios de leucocitos infectados. El análisis estadístico arrojó una diferencia significativa solo en el tratamiento de la parasitosis con dipropionato de imidocarb. En virtud de los resultados obtenidos con los tratamientos llevados a cabo con los diferentes fármacos, se concluye que ninguno es totalmente efectivo para la desaparición del parásito de la sangre, siendo el dipropionato de imidocarb el de mejor comportamiento.Canine hepatozoonosis is a parasitic disease, acquired by ingestion of ticks infected with protozoa of the genus Hepatozoon (H). Hepatozoon canis and Hepatozoon americanum are the two species that can infect dogs. The clinical presentation of Hepatozoon canis infection is highly variable and may be asymptomatic or show signs of mild to severe disease. In clinical hepatozoonosis, haematological tests reveal slight non regenerative anemia, marked neutrophilic leukocytosis with left shift and monocytosis. Diagnosis is made by the visualization of gamonts in neutrophils and monocytes in stained blood smears using an optical microscope. To date, there is no effective treatment for hepatozoonsis; imidocarb propionate is the most commonly used drug, although results are variable. The aim of this study was to evaluate three therapeutic options for the eradication of Hepatozoon spp. from blood of infected dogs. Three drugs (imidocarb dipropionate, toltrazuril and spiramycin) were evaluated in 18 naturally infected dogs. In all treated dogs the infection averages decreased, showing similar mean values of infected leukocytes. The statistical analysis showed a significant difference only in the treatment of this parasitosis with imidocarb dipropionate. It is concluded that none of the drugs are fully effective in removing the parasite from the blood, but imidocarb dipropionate showed the best results.Facultad de Ciencias Veterinaria

The Bauru Basin in São Paulo and its tetrapods

Funding Information: The authors thank the editors of Derbyana, especially its Editor-in-Chief Silvio T. Hiruma, for the invitation to participate in this volume dedicated to “Advances in Paleontology”. This contribution results from FAPESP grant 2020/07997-4, to which most of the authors are affiliated. We also thank the Derbyana ad-hoc reviewers, Drs. Agustin Martinelli and Fabiano Iori, for their helpful comments to the manuscript. FIGURE 6 – Cumulative chronological distribution of the tetrapod fossil record in the Bauru Basin of São Paulo (1913-2022) compared to science and technology funding metrics and events: A – For all tetrapods; grey bars indicate total records of tables 1-5; green line indicates taxonomic richness (grey lines in Tables 1-5); pink line indicates FAPESP budget in billions of reais between 1976 and 2021 (FAPESP 2022); blue line indicates CNPq, CAPES, and FINEP budget in millions of reais between 1996 and 2018 (ESCOBAR 2019). Events indicated by arrows correspond, in chronological sequence, to the foundations of USP, “Instituto Geográfico e Geológico”, FAPESP, Unicamp, UNESP, “Instituto Geológico”, and Monte Alto Museum of Paleontology, the implementations of the Qualis list, the Lattes curriculum, the CAPES Portal de Periódicos, and the CNPq “grant”, the foundation of the Marília Museum of Paleontology, the release of the first MCT/CNPq public call for “Strengthening National Paleontology”, and the foundation of “Pedro Candolo” Museum of Paleontology. B – Separately for each recorded tetrapod group, coloured lines indicate total of records in tables 1-5 of Anura = light blue, Crocodyliformes = red, Mammalia = purple, Sauropoda = green, Squamata = yellow, Testudines = orange, and Theropoda = dark blue. Publisher Copyright: Copyright © 2022 The Institute of Electronics, Information and Communication Engineers.The Bauru Basin bears one of the best sampled tetrapod paleofaunas of Brazil, with about 70% of this diversity collected from its deposits in São Paulo. Its fossils are known since the beginning of the 20th century, coming from all stratigraphic units of the Basin cropping-out in the state, i.e., Santo Anastácio, Araçatuba, Adamantina (alternatively divided into Vale do Rio do Peixe, Presidente Prudente, and São José do Rio Preto formations), and Marília formations. Identified taxa include rare anurans, mammals, and squamates, an important set of testudines, theropods (including birds), and sauropods, in addition to one of the most diverse crocodyliform faunas known worldwide. This congregates more than fifty unique taxonomic entities, including 42 formally described species. Based on biostratigraphic correlations (including tetrapods), on few absolute ages, and other sources of evidence, the Bauru Basin deposits in São Paulo seem to be chronologically restricted to the Late Cretaceous, but further investigation is much needed. Finally, the history of research with such fossils highlights the importance of public funding for research and decentralization of university education for the advancement of science.publishersversionpublishe

XAF1 as a modifier of p53 function and cancer susceptibility

Cancer risk is highly variable in carriers of the common TP53-R337H founder allele, possibly due to the influence of modifier genes. Whole-genome sequencing identified a variant in the tumor suppressor XAF1 (E134*/Glu134Ter/rs146752602) in a subset of R337H carriers. Haplotype-defining variants were verified in 203 patients with cancer, 582 relatives, and 42,438 newborns. The compound mutant haplotype was enriched in patients with cancer, conferring risk for sarcoma (P = 0.003) and subsequent malignancies (P = 0.006). Functional analyses demonstrated that wild-type XAF1 enhances transactivation of wild-type and hypomorphic TP53 variants, whereas XAF1-E134* is markedly attenuated in this activity. We propose that cosegregation of XAF1-E134* and TP53-R337H mutations leads to a more aggressive cancer phenotype than TP53-R337H alone, with implications for genetic counseling and clinical management of hypomorphic TP53 mutant carriers.Fil: Pinto, Emilia M.. St. Jude Children's Research Hospital; Estados UnidosFil: Figueiredo, Bonald C.. Instituto de Pesquisa Pelé Pequeno Principe; BrasilFil: Chen, Wenan. St. Jude Children's Research Hospital; Estados UnidosFil: Galvao, Henrique C.R.. Hospital de Câncer de Barretos; BrasilFil: Formiga, Maria Nirvana. A.c.camargo Cancer Center; BrasilFil: Fragoso, Maria Candida B.V.. Universidade de Sao Paulo; BrasilFil: Ashton Prolla, Patricia. Universidade Federal do Rio Grande do Sul; BrasilFil: Ribeiro, Enilze M.S.F.. Universidade Federal do Paraná; BrasilFil: Felix, Gabriela. Universidade Federal da Bahia; BrasilFil: Costa, Tatiana E.B.. Hospital Infantil Joana de Gusmao; BrasilFil: Savage, Sharon A.. National Cancer Institute; Estados UnidosFil: Yeager, Meredith. National Cancer Institute; Estados UnidosFil: Palmero, Edenir I.. Hospital de Câncer de Barretos; BrasilFil: Volc, Sahlua. Hospital de Câncer de Barretos; BrasilFil: Salvador, Hector. Hospital Sant Joan de Deu Barcelona; EspañaFil: Fuster Soler, Jose Luis. Hospital Clínico Universitario Virgen de la Arrixaca; EspañaFil: Lavarino, Cinzia. Hospital Sant Joan de Deu Barcelona; EspañaFil: Chantada, Guillermo Luis. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. St. Jude Children's Research Hospital; Estados UnidosFil: Vaur, Dominique. Comprehensive Cancer Center François Baclesse; FranciaFil: Odone Filho, Vicente. Universidade de Sao Paulo; BrasilFil: Brugières, Laurence. Institut de Cancerologie Gustave Roussy; FranciaFil: Else, Tobias. University of Michigan; Estados UnidosFil: Stoffel, Elena M.. University of Michigan; Estados UnidosFil: Maxwell, Kara N.. University of Pennsylvania; Estados UnidosFil: Achatz, Maria Isabel. Hospital Sirio-libanês; BrasilFil: Kowalski, Luis. A.c.camargo Cancer Center; BrasilFil: De Andrade, Kelvin C.. National Cancer Institute; Estados UnidosFil: Pappo, Alberto. St. Jude Children's Research Hospital; Estados UnidosFil: Letouze, Eric. Centre de Recherche Des Cordeliers; FranciaFil: Latronico, Ana Claudia. Universidade de Sao Paulo; BrasilFil: Mendonca, Berenice B.. Universidade de Sao Paulo; BrasilFil: Almeida, Madson Q.. Universidade de Sao Paulo; BrasilFil: Brondani, Vania B.. Universidade de Sao Paulo; BrasilFil: Bittar, Camila M.. Universidade Federal do Rio Grande do Sul; BrasilFil: Soares, Emerson W.S.. Hospital Do Câncer de Cascavel; BrasilFil: Mathias, Carolina. Universidade Federal do Paraná; BrasilFil: Ramos, Cintia R.N.. Hospital de Câncer de Barretos; BrasilFil: Machado, Moara. National Cancer Institute; Estados UnidosFil: Zhou, Weiyin. National Cancer Institute; Estados UnidosFil: Jones, Kristine. National Cancer Institute; Estados UnidosFil: Vogt, Aurelie. National Cancer Institute; Estados UnidosFil: Klincha, Payal P.. National Cancer Institute; Estados UnidosFil: Santiago, Karina M.. A.c.camargo Cancer Center; BrasilFil: Komechen, Heloisa. Instituto de Pesquisa Pelé Pequeno Principe; BrasilFil: Paraizo, Mariana M.. Instituto de Pesquisa Pelé Pequeno Principe; BrasilFil: Parise, Ivy Z.S.. Instituto de Pesquisa Pelé Pequeno Principe; BrasilFil: Hamilton, Kayla V.. St. Jude Children's Research Hospital; Estados UnidosFil: Wang, Jinling. St. Jude Children's Research Hospital; Estados UnidosFil: Rampersaud, Evadnie. St. Jude Children's Research Hospital; Estados UnidosFil: Clay, Michael R.. St. Jude Children's Research Hospital; Estados UnidosFil: Murphy, Andrew J.. St. Jude Children's Research Hospital; Estados UnidosFil: Lalli, Enzo. Institut de Pharmacologie Moléculaire et Cellulaire; FranciaFil: Nichols, Kim E.. St. Jude Children's Research Hospital; Estados UnidosFil: Ribeiro, Raul C.. St. Jude Children's Research Hospital; Estados UnidosFil: Rodriguez-Galindo, Carlos. St. Jude Children's Research Hospital; Estados UnidosFil: Korbonits, Marta. Queen Mary University of London; Reino UnidoFil: Zhang, Jinghui. St. Jude Children's Research Hospital; Estados UnidosFil: Thomas, Mark G.. Colegio Universitario de Londres; Reino UnidoFil: Connelly, Jon P.. St. Jude Children's Research Hospital; Estados UnidosFil: Pruett-Miller, Shondra. St. Jude Children's Research Hospital; Estados UnidosFil: Diekmann, Yoan. Colegio Universitario de Londres; Reino UnidoFil: Neale, Geoffrey. St. Jude Children's Research Hospital; Estados UnidosFil: Wu, Gang. St. Jude Children's Research Hospital; Estados UnidosFil: Zambetti, Gerard P.. St. Jude Children's Research Hospital; Estados Unido

Global Spatial Risk Assessment of Sharks Under the Footprint of Fisheries

Effective ocean management and conservation of highly migratory species depends on resolving overlap between animal movements and distributions and fishing effort. Yet, this information is lacking at a global scale. Here we show, using a big-data approach combining satellite-tracked movements of pelagic sharks and global fishing fleets, that 24% of the mean monthly space used by sharks falls under the footprint of pelagic longline fisheries. Space use hotspots of commercially valuable sharks and of internationally protected species had the highest overlap with longlines (up to 76% and 64%, respectively) and were also associated with significant increases in fishing effort. We conclude that pelagic sharks have limited spatial refuge from current levels of high-seas fishing effort. Results demonstrate an urgent need for conservation and management measures at high-seas shark hotspots and highlight the potential of simultaneous satellite surveillance of megafauna and fishers as a tool for near-real time, dynamic management

A communal catalogue reveals Earth's multiscale microbial diversity

Our growing awareness of the microbial world's importance and diversity contrasts starkly with our limited understanding of its fundamental structure. Despite recent advances in DNA sequencing, a lack of standardized protocols and common analytical frameworks impedes comparisons among studies, hindering the development of global inferences about microbial life on Earth. Here we present a meta-analysis of microbial community samples collected by hundreds of researchers for the Earth Microbiome Project. Coordinated protocols and new analytical methods, particularly the use of exact sequences instead of clustered operational taxonomic units, enable bacterial and archaeal ribosomal RNA gene sequences to be followed across multiple studies and allow us to explore patterns of diversity at an unprecedented scale. The result is both a reference database giving global context to DNA sequence data and a framework for incorporating data from future studies, fostering increasingly complete characterization of Earth's microbial diversity.Peer reviewe

A communal catalogue reveals Earth’s multiscale microbial diversity

Our growing awareness of the microbial world’s importance and diversity contrasts starkly with our limited understanding of its fundamental structure. Despite recent advances in DNA sequencing, a lack of standardized protocols and common analytical frameworks impedes comparisons among studies, hindering the development of global inferences about microbial life on Earth. Here we present a meta-analysis of microbial community samples collected by hundreds of researchers for the Earth Microbiome Project. Coordinated protocols and new analytical methods, particularly the use of exact sequences instead of clustered operational taxonomic units, enable bacterial and archaeal ribosomal RNA gene sequences to be followed across multiple studies and allow us to explore patterns of diversity at an unprecedented scale. The result is both a reference database giving global context to DNA sequence data and a framework for incorporating data from future studies, fostering increasingly complete characterization of Earth’s microbial diversity